{
    "relation": [
        [
            "",
            "STARTED",
            "RECEIVED ANY TREATMENT",
            "COMPLETED",
            "NOT COMPLETED",
            "Adverse event before Week 96",
            "Death before Week 96",
            "Lack of efficacy before Week 96",
            "Lost to follow up before Week 96",
            "Participant Imprisoned before Week 96",
            "Poor/non compliance before Week 96",
            "Pregnancy before Week 96",
            "No longer meets criteria before Week 96",
            "Withdrew consent before Week 96",
            "Changed address before Week 96",
            "Lost to follow-up at Week 96",
            "Poor/non compliance at Week 96]",
            "Pregnancy at Week 96",
            "Never treated",
            "Continuing on treatment"
        ],
        [
            "ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD",
            "440 [1]",
            "441 [3]",
            "301",
            "139",
            "13",
            "6",
            "16",
            "10",
            "1",
            "12",
            "5",
            "4",
            "5",
            "0",
            "1",
            "2",
            "1",
            "2",
            "61"
        ],
        [
            "LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD",
            "443 [2]",
            "437 [4]",
            "307",
            "136",
            "22",
            "5",
            "10",
            "13",
            "0",
            "16",
            "7",
            "3",
            "18",
            "1",
            "0",
            "0",
            "0",
            "3",
            "38"
        ]
    ],
    "pageTitle": "BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00272779?sect=X0156_01&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 6,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043060830.93/warc/CC-MAIN-20150728002420-00329-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 867962155,
    "recordOffset": 867941819,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Baseline Through Week 48 Participant Flow for 2 periods Participants were administered lopinavir (LPV) 400 mg or ritonavir (RTV) 100 mg twice daily along with food. Doses were taken approximately 12 hours apart while tenofovir (TDF) 300 mg once daily and emtricitabine (FTC) 200 mg once daily was administered at the same time as 1 of the 2 daily doses of LPV/RTV. LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD Participants were administered an oral dose of Atazanavir (ATV) 300 mg and ritonavir (RTV) 100 mg once daily along with food. Doses were taken 24 hours apart at the same time as fixed dose combination tenofovir (TDF) 300 mg plus emtricitabine (FTC) 200 mg once daily. ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD Description \u00a0 Reporting Groups Of 1057 HIV-infected participants, 174 participants were not randomized to receive study drug, the main reason being that they did not meet the study criteria (133/174; 76%). 441 randomized to ATV received any drug and 437 randomized to LPV received any drug. 438",
    "textAfterTable": "Adverse event on/after Week 48 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Death on/after Week 48 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Lack of efficacy on/after Week 48 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Poor/non compliance on/after Week \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 No longer meets criteria on/after Wk 48 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Pregnancy on/after Week 48 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}